SCHEMBL559092

SCHEMBL559092

O=C(N[C@H]1CC[C@H](O)CC1)c1ccc2cnc(N[C@H]3CC[C@H](O)CC3)nc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.51
MCHR1 Q99705 7/20 0.51
CCNE1 P24864 6/20 0.50
CDK2 P24941 6/20 0.50
ADRA2A P08913 4/20 0.50
HRH1 P35367 4/20 0.50
HTR2B P41595 4/20 0.50
ADRA1A P35348 2/20 0.49
MAPK8 P45983 2/20 0.49
MAPK10 P53779 2/20 0.49
BMPR1B O00238 1/20 0.48
BMPR1A P36894 1/20 0.48
TGFBR1 P36897 1/20 0.48
ACVRL1 P37023 1/20 0.48
ACVR1 Q04771 1/20 0.48
CSNK2A1 P68400 1/20 0.48
MAPK9 P45984 1/20 0.47
MAPK1 P28482 1/20 0.47
MAPK14 Q16539 1/20 0.46
CSNK2A2 P19784 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2263303 1.00 HPGDS (0.51) HPGDSMCHR1CCNE1CDK2ADRA2A
SCHEMBL558934 0.93 MCHR1 (0.46) HPGDSMCHR1CCNE1CDK2ADRA2A
SCHEMBL2262106 0.93 MCHR1 (0.46) HPGDSMCHR1CCNE1CDK2ADRA2A
SCHEMBL559398 0.93 MCHR1 (0.46) HPGDSMCHR1CCNE1CDK2ADRA2A
SCHEMBL558517 0.90 CSNK2A1 (0.58) CCNE1CDK2MAPK8MAPK10CSNK2A1
SCHEMBL558518 0.90 CSNK2A1 (0.58) CCNE1CDK2MAPK8MAPK10CSNK2A1
SCHEMBL558878 0.90 CDK2 (0.54) HPGDSMCHR1CCNE1CDK2BMPR1B
SCHEMBL2255518 0.90 CDK2 (0.54) HPGDSMCHR1CCNE1CDK2BMPR1B
SCHEMBL10166429 0.90 BRAF (0.53) HPGDSCCNE1CDK2MAPK1MAPK14
SCHEMBL558964 0.90 BRAF (0.53) HPGDSCCNE1CDK2MAPK1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 2012-02-09 US disclosed
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 2012-02-09 US disclosed
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 2012-02-09 US disclosed
US-7998978-B2 Substituted 2-amino-fused heterocyclic compounds PFIZER INC. (US) 2011-08-16 US disclosed
US-7998978-B2 Substituted 2-amino-fused heterocyclic compounds PFIZER INC. (US) 2011-08-16 US disclosed
US-7998978-B2 Substituted 2-amino-fused heterocyclic compounds PFIZER INC. (US) 2011-08-16 US disclosed
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-03-04 US disclosed
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-03-04 US disclosed
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS MAPK1, SLC5A1, ATF1 HPGDS 1716/4885MCHR1 1552/4885CCNE1 523/4885
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS MAPK1, SLC5A1, ATF1 HPGDS 1716/4885MCHR1 1552/4885CCNE1 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.